Acute high-altitude sickness (AHAS)
- A systemic disorder that affects individuals usually within 6– 48 hrs after ascent to high altitudes.
- Clinical features
- Odema of feet and hands
- Pulmonary oedema (HAPE= high-altitude pulmonary edema).
- Ocular findings include
- Retinal haemorrhages,
- Nerve fiber layer infarction,
- Papilledema
- Vitreous haemorrhage.
- Cerebral edema (HACE= high-altitude cerebral edema),
- Usually associated with pulmonary edema
- May occur in severe cases of AHAS.
- Symptoms of HACE include:
- Severe headache,
- Mental dysfunction (hallucinations, inappropriate behavior, reduced mental status),
- Neurologic abnormalities (ataxia, paralysis, cerebellar findings).
Acute mountain sickness (AMS)
- Most common form of AHAS,
- Symptoms of
- Nausea, headache, anorexia, dyspnoea, insomnia, and fatigue,
- Often assessed using the Lake Louise system.
- Incidence is
- ≈ 25% at 7,000 feet
- ≈ 50% at 15,000 feet
- Theory
- The unproven “tight-fit” hypothesis postulated that individuals with less compliant CSF systems (smaller ventricles and CSF spaces) were more vulnerable to AMS.
- Prevention:
- Gradual ascent,
- 2–4 day acclimatization at intermediate altitudes (especially to include sleeping at these levels),
- Avoidance of alcohol or hypnotics.
- Treatment of cerebral edema:
- Immediate descent and oxygen (6–12 L/min by NC or face-mask) are recommended.
- Dexamethasone 8mg PO or IV followed by 4mg q 6 hrs may help temporize